Clinical and Histologic Studies of Ovarian Carcinoma. Long Term Follow-Up of 990 Cases

Aure, J. Chr.; Kolstad, Per

doi:10.1097/00006254-197106000-00022

Cited by 62 publications

(80 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,6,11,12,21 It has been suggested that the endometrioid survival advantage may be a reflection of an earlier stage of presentation rather than an effect of histological type itself. 7,17 However, this survival advantage was still present for stage II and III diseases in our sample.…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7][8][9][10] Some authors have suggested that endometrioid pathology is associated with better overall survival than serous adenocarcinoma of the ovary. 4,[11][12][13][14][15][16] However, more recently, there has been speculation that this could be because the majority of these patients have early stage disease. 7,17 To our knowledge, there have been no published stage-for-stage comparisons of the 2 histological types to date.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Endometrioid epithelial ovarian cancer

Storey

Rush

Stewart

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared. METHODS. Between 1984 and 2004, baseline and follow‐up data were prospectively recorded on 1545 patients with ovarian cancer. Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary. Response to platinum‐based chemotherapy (PBC) overall survival, stage‐for‐stage median progression‐free survival (PFS), and cause‐specific median survival were compared. Independent predictors of survival were examined by using multivariate analyses. RESULTS. Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013). They presented more often with early disease (stage I and II; 50% vs 17%; P < .001), had less ascites, and had better performance status both overall and for stage II and III disease. More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage. Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001). This relation remained for stage II and III disease and for moderately and poorly differentiated tumors. Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone. Independent predictors of survival after PBC were histological type, debulking status, and disease stage. CONCLUSIONS. Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors. Cancer 2008. © 2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Endometrioid epithelial ovarian cancer

Storey

Rush

Stewart

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…6 The standard-of-care treatment for advanced ovarian cancer, defined by the International Federation of Gynecology and Obstetrics (FIGO) as stage IIB-IV, 7 consists of upfront cytoreductive surgery, followed by platinum-based intravenous chemotherapy. 8,9 Achieving resection of all macroscopic disease to lesions <1 cm, and preferably complete resection of all macroscopic disease, by upfront cytoreductive surgery offers the best prognosis for women with advanced ovarian cancer in terms of survival. 10,11 Median survival increases with 5.5% for every 10% gain in optimal surgical cytoreduction rate.…”

Section: Introductionmentioning

confidence: 99%

The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

Gerestein

Eijkemans

Jong

et al. 2009

BJOG

View full text Add to dashboard Cite

Objective Prognosis in women with ovarian cancer mainly depends on International Federation of Gynecology and Obstetrics stage and the ability to perform optimal cytoreductive surgery. Since ovarian cancer has a heterogeneous presentation and clinical course, predicting progression-free survival (PFS) and overall survival (OS) in the individual patient is difficult. The objective of this study was to determine predictors of PFS and OS in women with advanced stage epithelial ovarian cancer (EOC) after primary cytoreductive surgery and first-line platinum-based chemotherapy.Design Retrospective observational study.Setting Two teaching hospitals and one university hospital in the south-western part of the Netherlands.Population Women with advanced stage EOC.Methods All women who underwent primary cytoreductive surgery for advanced stage EOC followed by first-line platinumbased chemotherapy between January 1998 and October 2004 were identified. To investigate independent predictors of PFS and OS, a Cox' proportional hazard model was used. Nomograms were generated with the identified predictive parameters.Main outcome measures The primary outcome measure was OS and the secondary outcome measures were response and PFS.Results A total of 118 women entered the study protocol. Median PFS and OS were 15 and 44 months, respectively. Preoperative platelet count (P = 0.007), and residual disease <1 cm (P = 0.004) predicted PFS with a optimism corrected c-statistic of 0.63. Predictive parameters for OS were preoperative haemoglobin serum concentration (P = 0.012), preoperative platelet counts (P = 0.031) and residual disease <1 cm (P = 0.028) with a optimism corrected c-statistic of 0.67.Conclusion PFS could be predicted by postoperative residual disease and preoperative platelet counts, whereas residual disease, preoperative platelet counts and preoperative haemoglobin serum concentration were predictive for OS. The proposed nomograms need to be externally validated.

show abstract

“…13 In spite of the imprimatur of several international organizations, the concept of borderline ovarian epithelial tumors was not universally accepted. The vanguard of proponents was led by pathologists and gynecologists in Scandinavia, 8,10,11,14 and a few in the United States 9,[15][16][17][18][19] and Australia. 20,21 Some pathologists in leading academic medical centers refused to incorporate borderline tumor into their diagnostic nomenclature, routinely diagnosing most serous and mucinous borderline tumors as welldifferentiated cystadenocarcinoma until quite late in the 20th century.…”

mentioning

confidence: 99%

Borderline epithelial tumors of the ovary

2005

View full text Add to dashboard Cite

The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors. Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type. Borderline tumors of all surface epithelial cell types have been studied. The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review. Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors. The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei. All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline tumors and pertinent information on their treatment and prognosis. Modern Pathology (2005) 18, S33-S50.

show abstract

Clinical and Histologic Studies of Ovarian Carcinoma. Long Term Follow-Up of 990 Cases

Cited by 62 publications

References 0 publications

Endometrioid epithelial ovarian cancer

Endometrioid epithelial ovarian cancer

The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

Borderline epithelial tumors of the ovary

Contact Info

Product

Resources

About